Skip to main content

MDxHealth Signs Middle East Distribution Deal for Prostate Cancer Test

NEW YORK (GenomeWeb) – MDxHealth announced today that it has signed a distribution agreement with IPS Genomix for its SelectMDx for Prostate Cancer test in the Middle East.

IPS Genomix will distribute the test in Lebanon, Egypt, the United Arab Emirates, Saudi Arabia, Oman, Bahrain, Qatar, and Jordan. The company will also handle reimbursement for SelectMDx within the Middle East. MDxHealth, meanwhile, will perform the SelectMDx testing service in its ISO-certified clinical diagnostic laboratory in Nijmegen, the Netherlands.

Financial terms of the agreement were not disclosed.

SelectMDx is a urine-based molecular diagnostic test that assesses a man's risk for prostate cancer. It helps identify men at increased risk of harboring aggressive, potentially lethal prostate cancer who may benefit most from a prostate biopsy and earlier detection. The test delivers a negative predictive value of 98 percent for clinically significant disease, MDxHealth said.

"We are delighted to announce our collaboration with IPS Genomix for the promotion of SelectMDx across the Middle East," MDxHealth CEO Jan Groen said in a statement. "IPS Genomix is the ideal partner to bring SelectMDx to physicians, helping to improve both the quality of care and outcomes for patients suspected of harboring aggressive prostate cancer."

The agreement marks the latest in a series of distribution arrangements MDxHealth has struck recently for SelectMDx, including one covering the UK in March.